Toripalimab
Toripalimab (Loqtorzi, Topalliance Biosciences Europe Limited) has 2 EU-approved indications in 2 tumour types.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Oesophageal cancer1 | |||
None | + cisplatin and paclitaxel | 1L advanced | Squamous cell carcinoma only |
| Nasopharyngeal carcinoma1 | |||
None | + cisplatin and gemcitabine | 1L advanced | Recurrent disease not amenable to surgery or radiotherapy |
Full text of section 4.1 (therapeutic indications)
LOQTORZI, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. LOQTORZI, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Label history
5 changes to the Loqtorzi label since 2025, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes